Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

LGBTQ+

- PMLiVE

Infographic: Advantages & Disadvantages of Different Meeting Formats

Discover the unique pros and cons of in-person, hybrid, synchronous virtual, and asynchronous virtual meetings with our detailed infographic. Perfect for anyone planning efficient and engaging meetings, especially in pharmaceutical...

Impetus Digital

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by EC for younger eosinophilic oesophagitis patients

Dupixent is now the first drug in the EU indicated for use in this patient population

- PMLiVE

Novo Nordisk and Ascendis enter $285m partnership for once-monthly GLP-1 drug

The companies will use Ascendis’ TransCon technology to develop therapies for metabolic and cardiovascular diseases

- PMLiVE

Chiesi and Oak Hill enrol first European patient in phase 2b premature birth study

The trial is evaluating OHB-607 for preventing bronchopulmonary dysplasia and other complications

- PMLiVE

Johnson & Johnson’s Balversa granted MHRA approval in bladder cancer

Approximately 10,500 people are diagnosed with bladder cancer every year in the UK

- PMLiVE

FDA approves Journey Medical’s Emrosi to treat inflammatory lesions of rosacea

The long-term skin condition affects more than 16 million people in the US

- PMLiVE

GCI Health appoints Annalise Coady as president, UK market lead and EMEA head of growth

Coady was previously group president at Real Chemistry

- PMLiVE

FINDING OPPORTUNITIES IN YOUR DIGITAL MARKETING STRATEGY

Digital marketing serves as a critical component within a successful omnichannel strategy, guaranteeing seamless experiences for healthcare professionals and patients across various online platforms. It plays a pivotal role in...

IGNIFI

- PMLiVE

AstraZeneca’s Fasenra approved by EC to treat rare inflammatory disease EGPA

Eosinophilic granulomatosis with polyangiitis affects approximately 118,000 people globally

- PMLiVE

GSK expands immunology pipeline by acquiring Chimagen’s CMG1A46 in deal worth $850m

The company plans to develop the candidate for autoimmune diseases such as lupus

- PMLiVE

UCB shares ‘encouraging’ data for Alzheimer’s disease candidate bepranemab

The drug showed benefits across key secondary endpoints, including tau accumulation

- PMLiVE

Why is storytelling changing the way we do health comms?

Principal Medical Writer, Dr Alexandra Loveday explores the importance of storytelling in health communications.

Mednet

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links